Brain local and regional neuroglial alterations in alzheimer´s disease: Cell types, responses and implications

Current Alzheimer Research

Volumn 13, Issue 4, 2016, Pages 321-342

  Toledano, Adolfo ^a   Álvarez, María Isabel ^a   Toledano Díaz, Adolfo ^b   Merino, José Joaquín ^c   Rodríguez, José Julio ^d,e  

^a INSTITUTO CAJAL   (Spain)

^b INIA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d BASQUE FOUNDATION FOR SCIENCE   (Spain)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Alzheimer s disease; Astrogliosis; Glial eurodegeneration neuroprotection; Glial plasticity; Microgliosis; Neuroglial cells; Reactive neuroglial cells

Indexed keywords

ALZHEIMER DISEASE; ASTHENIA; ASTROCYTE; ASTROCYTOSIS; BRAIN ATROPHY; DEGENERATIVE DISEASE; GLIA; GLIA CELL; GLIOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; MACROGLIA; MICROGLIA; MORPHOLOGY; NERVE DEGENERATION; NEUROPROTECTION; OLIGODENDROGLIA; OLIGODENDROGLIOSIS; PRIORITY JOURNAL; REVIEW; BRAIN; CLASSIFICATION; COMPLICATION; METABOLISM; NERVOUS SYSTEM DISEASES; PATHOLOGY;

NERVE PROTEIN;

ALZHEIMER DISEASE; BRAIN; HUMANS; NERVE TISSUE PROTEINS; NERVOUS SYSTEM DISEASES; NEUROGLIA;

EID: 84964033796     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666151116141217     Document Type: Review

References (171)

1. Ortega y Gasset J. Meditaciones del Quijote. Madrid: Publicaciones de la Residencia de Estudiantes (1914).
2. Virchow R. Die Cellularpathologie in ihrer Begrundung auf physiologische und pathologische Gewebelehre. Berlin: Verlag (1858).
3. Ramon, Cajal S. Histologie du systeme nerveux de l´homme et des vertebres (translated by L. Azoulay), vols I and II. Paris: Maloine (1909-1911). (Reprinted 1952 and 1955. Madrid: Consejo Superior de Investigaciones Cientificas).
4. Ramon, Cajal S. Contribucion al conocimiento de la neuroglia del cerebro humano. Trab Lab Invest Biol 11: 255-315 (1913).
5. Ramon A, Cajal S. Contribution a la connaissance de la nevroglie cerebrale et cerebelleuse dans la paralysie generale progressive. Trav. Lab Recher Biol Univ Madrid 23: 157-216 (1925).
6. Retzius G. Die Neuroglia des Gehirns beim Menschen und bei Saugethieren: Die Neuroglia des Kleinhirns. Biologische Untersuchungen. Neue Folge 6: 16-20 (1894).
7. Bergmann C. Notiz ubre einige Structurverhaltnisse der Cerebellum und Ruckenmarks. Z Rationelle Med 8: 360-363 (1857).
8. Golgi C. Sulla fina anatomia del cervelletto umano. Lecture, Ist. Lomb Sci Lett (Milano) 8, January (1874). (Reprinted 1903, in: Opera Omnia, vol. 1: Istologia normale, 1870-1883. Milan: Ulrico Hoepli pp. 99-111).
9. Terrazas R. Notas sobre la neuroglia del cerebelo y el crecimiento de los elementos nerviosos. Rev Trim Micrograf II 49-65 (1897).
10. Del Rio Hortega P. El “tercer elemento” de los centros nerviosos. Poder fagocitario y movilidad de la microglia. Bol Soc Esp Biol 8: 68-82 (1919).
11. Del Rio Hortega P. La glia de escasas radiaciones (oligodendroglia). Bol Real Soc Esp Hist Nat 21: 63-92 (1921).
12. Del Rio Hortega P. Histogenesis y evolucion normal, exodo y distribucion regional de la microglia. Mem Real Soci Esp Hist Nat 11: 213-268 (1921).
13. Penfield W. Neuroglia: normal and pathological. In: Penfield W, Ed. Cytology and cellular pathology of the nervous system. Vol 2. New York: PB Hoeberr Inc. pp. 423-479 (1932).
14. Magistretti PJ. Role of glutamate in neuron-glia metabolic coupling. Am J Clin Nutr 90: 875S-880S (2009).
15. Bankston AN, Mandler MD, Feng Y. Oligodendroglia and neurotrophic factors in neurodegeneration. Neurosci Bull 29: 216-228 (2013).
16. Rodriguez JJ, Olabarria M, Chvatal A, Verkhratsky A. Astroglia in dementia and Alzheimer’s disease. Cell Death Differ 16: 378-385 (2009).
17. Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ. Astrocytes in Alzheimer’s disease. Neurotherapeutics 7: 399-412 (2010).
18. Verkhratsky A, Rodriguez JJ, Parpura V. Astroglia in neurological diseases. Future Neurol 8: 149-158 (2013).
19. Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, Haydon PG, et al. Glial cells in (patho)physiology. J Neurochem 121: 4-27 (2012).
20. Vernadakis A. Glia-neuron intercommunications and synaptic plasticity. Prog Neurobiol 49: 185-214 (1996).
21. Nedergaard M, Ransom B, Goldman SA. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci 26: 523-530 (2003).
22. Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell 158: 15-24 (2014).
23. Tremblay ME, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. The role of microglia in the healthy brain. J Neurosci 31: 16064-16069 (2011).
24. Morris GP, Clark IA, Zinn R, Vissel B. Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research. Neurobiol Learn Mem 105: 40-53 (2013).
25. Ota Y, Zanetti AT, Hallock RM. The role of astrocytes in the regulation of synaptic plasticity and memory formation. Neural Plast 2013: 185463 (2013).
26. Papa M, De Luca C, Petta F, Alberghina L, Cirillo G. Astrocyteneuron interplay in maladaptive plasticity. Neurosci Biobehav Rev 42: 35-54 (2014).
27. Allaman I, Belanger M, Magistretti PJ. Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci 34: 76-87 (2011).
28. Stuchlik A. Dynamic learning and memory, synaptic plasticity and neurogenesis: an update. Front Behav Neurosci 8: 106 (2014).
29. Viola GG, Rodrigues L, Americo JC, Hansel G, Vargas RS, Biasibetti R, et al. Morphological changes in hippocampal astrocytes induced by environmental enrichment in mice. Brain Res 1274: 47-54 (2009).
30. Xavier AL, Menezes JR, Goldman SA, Nedergaard M. Fine-tuning the central nervous system: microglial modelling of cells and synapses. Philos Trans R Soc Lond B Biol Sci 369 (1654) (2014).
31. Perez-Alvarez A, Navarrete M, Covelo A, Martin ED, Araque A. Structural and functional plasticity of astrocyte processes and dendritic spine interactions. J Neurosci 34: 12738-12744 (2014).
32. Araque A, Carmignoto G, Haydon PG, Oliet SH, Robitaille R, Volterra A. Gliotransmitters travel in time and space. Neuron 81: 728-739 (2014).
33. Lim D, Ronco V, Grolla AA, Verkhratsky A, Genazzani AA. Glial calcium signalling in Alzheimer’s disease. Rev Physiol Biochem Pharmacol 167: 45-65 (2014).
34. Meucci O, Fatatis A, Simen AA, Miller RJ. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci USA 97: 8075-8080 (2000).
35. Nedergaard M, Verkhratsky A. Artifact versus reality--how astrocytes contribute to synaptic events. Glia 60: 1013-1023 (2012).
36. Mosher KI, Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer’s disease. Biochem Pharmacol 88: 594-604 (2014).
37. Nagelhus EA, Amiry-Moghaddam M, Bergersen LH, Bjaalie JG, Eriksson J, Gundersen V, et al. The glia doctrine: addressing the role of glial cells in healthy brain ageing. Mech Ageing Dev 134: 449-459 (2013).
38. Herber DL, Maloney JL, Roth LM, Freeman MJ, Morgan D, Gordon MN. Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia 53: 382-391 (2006).
39. Benarroch EE. Microglia: Multiple roles in surveillance, circuit shaping, and response to injury. Neurology 81: 1079-1088 (2013).
40. Verkhratsky A, Marutle A, Rodriguez-Arellano JJ, Nordberg A. Glial asthenia and functional paralysis: a new perspective on neurodegeneration and Alzheimer’s disease. Neuroscientist pii: 1073858414547132 (2014).
41. Orre M, Kamphuis W, Osborn LM, Jansen AH, Kooijman L, Bossers K. Isolation of glia from Alzheimer’s mice reveals inflammation and dysfunction. Neurobiol Aging 35: 2746-2760 (2014).
42. Colton C, Wilcock DM. Assessing activation states in microglia. CNS Neurol Disord Drug Targets 9: 174-191 (2010).
43. Ramon, Cajal, S. Degeneration and Regeneration of the Nervous System. New York: Harper Press (1969).
44. Achucarro N, Gayarre M. Contribucion al estudio de la neuroglia en la corteza de la demencia senil y su participacion en la alteracion celular de Alzheimer. Trab Lab Invest Biol Univ Madrid 12: 68-83 (1914).
45. Achucarro N, Gayarre M. La corteza cerebral en la demencia paralitica con el nuevo metodo del oro y sublimado de Cajal. Trab Lab Invest Biol Univ Madrid 12: 1-38 (1914).
46. Pekny M, Pekna M. Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev 94: 1077-1098 (2014).
47. Astrand R, Unden J, Romner B. Clinical use of the calcium-binding S100B protein. Methods Mol Biol 963: 373-384 (2013).
48. Azizi G, Mirshafiey A. The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis. Immunopharmacol Immunotoxicol 34: 881-895 (2012).
49. Rodriguez JJ, Yeh CY, Terzieva S, Olabarria M, Kulijewicz-Nawrot M, Verkhratsky A. Complex and region-specific changes in astroglial markers in the aging brain. Neurobiol Aging 35: 15-23 (2014).
50. Toledano A, Alvarez MI, Toledano-Diaz A. Diversity and variability of the nicotine effects on different brain cortical regions. Therapeutic and toxicologic implications. Central Nervous Syst Agents Med Chem 10: 180-206 (2010)
51. Alvarez MI, Rivas L, Lacruz C, Toledano A. Astroglial cell subtypes in the cerebella of normal adults, elderly adults, and patients with Alzheimer’s disease: A histological and immunohistochemical comparison. Glia 62: 287-312 (2015).
52. Nowakowski RS, Rakic P. The mode of migration of neurons to the hippocampus: a Golgi and electron microscopic analysis in foetal rhesus monkey. J Neurocytol 8: 697-718 (1979).
53. Agnati LF, Cortelli P, Pettersson R, Fuxe K. The concept of trophic units in the central nervous system. Prog Neurobiol 46: 561-574 (1995).
54. Reichenbach A, Derouiche A, Kirchhoff F. Morphology and dynamics of perisynaptic glia. Brain Res Rev 63: 11-25 (2010)
55. Verkhratsky A, Nedergaard M. Astroglial cradle in the life of the synapse. Philos Trans R Soc Lond B Biol Sci 369(1654): 20130595 (2014).
56. Oberheim NA, Takano T, Han X, He W, Lin JH, Wang F, et al. Uniquely hominid features of adult human astrocytes. J Neurosci 29: 3276-3287 (2009).
57. Bushong EA, Martone ME, Jones YZ, Ellisman MH. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. J Neurosci 22: 183-192 (2002).
58. Halassa MM, Fellin T, Takano H, Dong JH, Haydon PG. Synaptic islands defined by the territory of a single astrocyte. J Neurosci 27: 6473-6477 (2007).
59. Oberheim NA, Goldman SA, Nedergaard M. Heterogeneity of astrocytic form and function. Meth Mol Biol 814: 23-45 (2012).
60. Goldman SA, Nedergaard M, Windrem MS. Modeling cognition and disease using human glial chimeric mice. Glia 63: 1483-1493 (2015).
61. Tsai HH, Li H, Fuentealba LC, Molofsky AV, Taveira-Marques R, Zhuang H, et al. Regional astrocyte allocation regulates CNS synaptogenesis and repair. Science 337: 358-362 (2012).
62. Dal Pra I, Chiarini A, Pacchiana R, Gardenal E, Chakravarthy B, Whitfield JF, et al. Calcium-sensing receptors of human astrocyteneuron teams: amyloid-β-driven mediators and therapeutic targets of Alzheimer’s disease. Curr Neuropharmacol 12: 353-364 (2014).
63. Lecrux C, Hamel E. The neurovascular unit in brain function and disease. Acta Physiol (Oxf) 203: 47-59 (2011).
64. Verkhratsky A, Nedergaard M, Hertz L. Why are astrocytes important? Neurochem Res 40: 389-401 (2015).
65. Sahlender DA, Savtchouk I, Volterra A. What do we know about gliotransmitter release from astrocytes? Philos Trans R Soc Lond B Biol Sci 369(1654): 20130592 (2014).
66. Bezzi P, Volterra A. Imaging exocytosis and recycling of synapticlike microvesicles in astrocytes. Cold Spring Harb Protoc 2014(5) pii: pdb.prot081711 (2014).
67. Mitew S, Kirkcaldie MT, Dickson TC, Vickers JC. Altered synapses and gliotransmission in Alzheimer’s disease and AD model mice. Neurobiol Aging 34: 2341-2351 (2013).
68. Martineau M. Gliotransmission: focus on exocytotic release of Lglutamate and D-serine from astrocytes. Biochem Soc Trans 41: 1557-61 (2013).
69. Iliff JJ, Nedergaard M. Is there a cerebral lymphatic system? Stroke 44: S93-S95 (2013).
70. Serrano-Pozo A, Muzikansky A, Gomez-Isla T, Growdon JH, Betensky RA, Frosch MP, et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol 72: 462-471 (2013).
71. Serrano-Pozo A, Gomez-Isla T, Growdon JH, Frosch MP, Hyman BT. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am J Pathol 182: 2332-2344 (2013).
72. Kamphuis W, Mamber C, Moeton M, Kooijman L, Sluijs JA, Jansen AH, et al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One 7(8): e42823 (2012).
73. Kamphuis W, Middeldorp J, Kooijman L, Sluijs JA, Kooi EJ, Moeton M, et al. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer’s disease. Neurobiol Aging 35: 492-510 (2014).
74. Kamphuis W, Kooijman L, Orre M, Stassen O, Pekny M, Hol EM. GFAP and vimentin eficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer’s disease. Glia 63: 1036-1056 (2015).
75. Mathur R, Ince PG, Minett T, Garwood CJ, Shaw PJ, Matthews FE, et al. A reduced astrocyte response to β-amyloid plaques in the ageing brain associates with cognitive impairment. PLoS One 10(2): e0118463 (2015).
76. Whitaker-Azmitia PM, Wingate M, Borella A, Gerlai R, Roder J, Azmitia EC. Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer’s disease and Down’s syndrome. Brain Res 776: 51-60 (1997).
77. Yang Y, Vidensky S, Jin L, Jie C, Lorenzini I, Frank M, Rothstein J. Molecular comparison of GLT1+ and ALDH1L1+ astrocytes in vivo in astroglial reporter mice. Glia 59: 200-207 (2011).
78. Meeker KD, Meabon JS, Cook DG. Partial Loss of the Glutamate Transporter GLT-1. Alters Brain Akt and Insulin Signaling in a Mouse Model of Alzheimer’s Disease. J Alzheimers Dis 45: 509-520 (2015).
79. Kulijewicz-Nawrot M, Sykova E, Chvatal A, Verkhratsky A, Rodriguez JJ. Astrocytes and glutamate homoeostasis in Alzheimer’s disease: a decrease in glutamine synthetase, but not in glutamate transporter-1, in the prefrontal cortex. ASN Neuro 5: 273-282 (2013).
80. Fernandez-Vizarra P, Fernandez AP, Castro-Blanco S, Encinas JM, Serrano J, Bentura ML, et al. Expression of nitric oxide system in clinically evaluated cases of Alzheimer’s disease. Neurobiol Dis 15: 287-305 (2004).
81. Lee M, Schwab C, Yu S, McGeer E, McGeer PL. Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide. Neurobiol Aging 30: 1523-1534 (2009).
82. Monzon-Mayor M, Alvarez M, Arbelo-Galvan J, Romero-Aleman M, Yanes C, et al. Long-term evolution of local, proximal and remote astrocyte responses after diverse nucleus basalis lesioning (an experimental Alzheimer model): GFAP immunocytochemical study. Brain Res 865: 245-258 (2000).
83. Kalman M. GFAP expression withdraws—a trend of glial evolution? Brain Res Bull 57: 509-511 (2002).
84. Stepień T, Wierzba-Bobrowicz T, Lewandowska E, Szpak G. Morphological and quantitative analysis of cerebellar cortical cells in Alzheimer’s disease. Folia Neuropathol 50: 250-260 (2012).
85. Toledano A, Alvarez MI, Rivas L, Lacruz C, Martinez-Rodriguez R. Amyloid precursor protein in the cerebellar cortex of Alzheimer’s disease patients devoid of cerebellar s-amyloid deposits. Immunocytochemical study of five cases. J Neural Trans 106: 1151-1169 (1999).
86. Sillevis Smitt PAE, Van der Loos C, Vianney de Jong JMB, Troost D. Tissue fixation methods alter the immunohistochemical demonstrability of neurofilament proteins, synpatophysin and glial fibrillary acidic protein in human cerebellum. Acta Histochem 95: 13-21 (1993).
87. Suarez I, Bodega G, Arilla E, Felipo V, Fernandez B. The expression of nNOS, iNOS and nitrotyrosine is increased in the rat cerebral cortex in experimental hepatic encephalopathy. Neuropathol Appl Neurobiol 32: 594-604 (2006).
88. Zimmer C, Sampaolo S, Sharma HS, Cervos-Navarro J. Altered glial fibrillary acidic protein immunoreactivity in rat brain following chronic hypoxia. Neuroscience 40: 353-361 (1991).
89. Berciano MT, Andres MA, Calle E, Lafarga M. Age-induced hypertrophy of astrocytes in rat supraoptic nucleus: a cytological, morphometric, and immunocytochemical study. Anat Rec 243: 129-144 (1995).
90. Day RJ, Frank AT, O´Callaghan JP, Jones BC, Anderson JE. The effect of age and testosterone on the expression of glial fibrillary acidic protein in the rat cerebellum. Exp Neurol 151: 343-346 (1998).
91. Herx LM, Yong VW. Interleukin-1 beta is required for the early evolution of reactive astrogliosis following CNS lesion. J Neuropathol Exp Neurol 60: 961-971 (2001).
92. Takeda K, Sawamura S, Sekiyama H, Tamai H, Hanaoka K. Effect of methylprednisolone on neuropathic pain and spinal glial activation in rats. Anesthesiology 100: 1249-1257 (2004).
93. Akiyama H, Mori H, Saido T, Kondo H, Ikeda K, Mc Geer PL. Occurrence of the diffuse amyloid Abeta-containing glial cells in the cerebral cortex of patients with Alzheimer´s disease. Glia 25: 324-331 (1991).
94. Eddleston M, Mucke L. Molecular profile of reactive astrocytes— implications for their role in neurologic disease. Neuroscience 54: 15-36 (1993).
95. Guo L, Sawkar A, Zasadzki M, Watterson DM, Van Eldik LJ. Similar activation of glial cultures from different rat brain regions by neuroinflammatory stimuli and downregulation of the activation by a new class of small molecule ligands. Neurobiol Aging 22: 975-981 (2001).
96. Jorgensen MB, Finsen BR, Jensen MB, Castellano B, Diemer NH, Zimmer J. Microglial and astroglial reactions to ischemic and kainic acid-induced lesions of the adult rat hippocampus. Exp Neurol 20: 70-88 (1993).
97. Yeh CY, Vadhwana B, Verkhratsky A, Rodriguez JJ. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer’s disease. ASN Neuro 3: 271-279 (2011).
98. Kulijewicz-Nawrot M, Verkhratsky A, Chvatal A, Sykova E, Rodriguez JJ. Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer’s disease. J Anat 221: 252-262 (2012).
99. Yeh CY, Verkhratsky A, Terzieva S, Rodriguez JJ. Glutamine synthetase in astrocytes from entorhinal cortex of the triple transgenic animal model of Alzheimer’s disease is not affected by pathological progression. Biogerontology 14: 777-787 (2013).
100. Benarroch EE. Oligodendrocytes: Susceptibility to injury and involvement in neurologic disease. Neurology 72: 1779-1785 (2009).
101. Schools GP, Zhou M, Kimelberg HK. Electrophysiologically "complex" glial cells freshly isolated from the hippocampus are immunopositive for the chondroitin sulfate proteoglycan NG2. J Neurosci Res 73: 765-777 (2003).
102. Levine JM, Card JP. Light and electron microscopic localization of a cell surface antigen (NG2) in the rat cerebellum: association with smooth protoplasmic astrocytes. J Neurosci 7: 2711-2720 (1987).
103. Crawford AH, Stockley JH, Tripathi RB, Richardson WD, Franklin RJ. Oligodendrocyte progenitors: adult stem cells of the central nervous system? Exp Neurol 260: 50-55 (2014).
104. Franklin RJ, ffrench-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 8: 624-634 (2012).
105. Kipp M, Victor M, Martino G, Franklin RJ. Endogeneous remyelination: findings in human studies. CNS Neurol Disord Drug Targets 11: 598-609 (2012).
106. Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 16: 1211-1218 (2013).
107. Furusho M, Roulois AJ, Franklin RJ, Bansal R. Fibroblast growth factor signaling in oligodendrocyte-lineage cells facilitates recovery of chronically demyelinated lesions but is redundant in acute lesions. Glia (in press) doi: 10.1002/glia.22838. (2015).
108. Franklin RJ, Gallo V. The translational biology of remyelination: past, present, and future. Glia 62: 1905-15 (2014).
109. Del Rio-Hortega P. Microglia. In: Cytology and Cellular Pathology of the Nervous System, Vol. 2. (Ed: Penfield W). New York: Hafner pp. 483-534 (1932).
110. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2(1): a006346 (2012).
111. Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernandez J, Campos-Pena V. Inflammatory process in Alzheimer’s Disease. Front Integr Neurosci 7: 59 (2013).
112. Prinz M, Priller J, Sisodia SS, Ransohoff RM. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 14: 1227-1235 (2011).
113. Li T, Pang S, Yu Y, Wu X, Guo J, Zhang S. Proliferation of parenchymal microglia is the main source of microgliosis after ischaemic stroke. Brain 136: 3578-3588 (2013).
114. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308: 1314-1318 (2005).
115. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature 451: 720-724 (2008).
116. Masliah E, Mallory M, Hansen L, Alford M, Albright T, Terry R, et al. Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer’s disease. Acta Neuropathol 83: 12-20 (1991).
117. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localization of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57: 1-9 (1998).
118. Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain (in press) doi: pii: awv081(2015).
119. Zhu Y, Hou H, Rezai-Zadeh K, Giunta B, Ruscin A, Gemma C, et al. CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer’s disease mice. J Neurosci 31: 1355-1365 (2011).
120. Matsumura A, Suzuki S, Iwahara N, Hisahara S, Kawamata J, Suzuki H, et al. Temporal changes of CD68 and α7 nicotinic acetylcholine receptor expression in microglia in Alzheimer’s diseaselike mouse models. J Alzheimers Dis 44: 409-423 (2015).
121. Perry RT, Collins JS, Wiener H, Acton R, Go RC. The role of TNF and its receptors in Alzheimer’s disease. Neurobiol Aging 22: 873-883 (2001).
122. Boche D, Perry VH, Nicoll JA. Review: activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol 39: 3-18 (2013).
123. Town T, Nikolic V, Tan J. The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflamm 2: 24 (2005).
124. Colton CA. Heterogeneity of Microglial Activation in the Innate Immune Response in the Brain. J Neuroimmune Pharmacol 4: 399-418 (2009).
125. Chhor V, Le Charpentier T, Lebon S, Ore MV, Celador IL, Josserand J, et al. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun 32: 70-85 (2013).
126. Han J, Ulevitch RJ. Limiting inflammatory responses during activation of innate immunity. Nat Immunol 6: 1198-1205 (2005).
127. Lee S, Xu G, Jay TR, Bhatta S, Kim KW, Jung S, Landreth GE, et al. Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. J Neurosci 34: 12538-12546 (2014).
128. Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques. Nat Commun 6: 6176 (2015).
129. Ferretti MT, Bruno MA, Ducatenzeiler A, Klein WL, Cuello AC. Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer’s disease. Neurobiol Aging 33: 1329-1342 (2012).
130. Guichard C, Pedruzzi E, Fay M, Ben Mkaddem S, Coant N, Daniel F, Ogier-Denis E.[The Nox/Duox family of ROS-generating NADPH oxidases]. Med Sci (Paris) 22: 953-959 (2006).
131. Frautschy SA, Cole GM, Baird A. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer betaamyloid. Am J Pathol 140: 1389-1399 (1992).
132. Collins JM, King AE, Woodhouse A, Kirkcaldie MT, Vickers J. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer’s disease Exp Neurol 267: 219-229 (2015).
133. Rodriguez JJ, Noristani HN, Hilditch T, Olabarria M, Yeh CY, Witton J, et al. Increased densities of resting and activated microglia in the dentate gyrus follow senile plaque formation in the CA1 subfield of the hippocampus in the triple transgenic model of Alzheimer’s disease. Neurosci Lett 552: 129-34 (2013).
134. Glezer I, Simard AR, Rivest S. Neuroprotective role of the innate immune system by microglia. Neuroscience 147: 867-883 (2007).
135. Mosser D.M. The many faces of macrophage activation. J Leukoc Biol 73: 209-212 (2003).
136. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 3: 23-35 (2003).
137. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 13: 453-461 (2008).
138. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964 (2005).
139. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflamm 3: 27-39 (2006).
140. Barger SW, Horster D, Furukawa K, Goodman Y, Krieglstein J, Mattson MP. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci USA 92: 9328-9332 (1995).
141. Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K. Cerebral pattern of pro-and anti-inflammatory cytokines in dementias. Brain Res Bull 61: 255-260 (2003).
142. Szczepanik AM, Funes S, Petko W, Ringheim GE. IL-4, IL-10 and IL-13 modulate A beta(1--42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J Neuroimmunol 113: 49-62 (2001).
143. Delacourte A. General and dramatic glial reaction in Alzheimer brains. Neurology 40: 33-37 (1990).
144. Beach TG, Walker R, McGeer EG. Patterns of gliosis in Alzheimer’s disease and aging cerebrum. Glia 2: 420-436 (1989).
145. Brun A, Liu X, Erikson C. Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer´s disease and in frontal lobe degeneration. Neurodegeneration 4: 171-177 (1995).
146. Serrano-Pozo A, Mielke ML, Gomez-Isla T, Betensky RA, Growdon JH, Frosch MP, Hyman BT. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol 179: 1373-1384 (2011).
147. Toledano A, Alvarez MI, Lopez-Rodriguez AB, Toledano-Diaz A, Fernandez-Verdecia CI. Does Alzheimer’s disease exist in all primates? Alzheimer pathology in non-human primates and its pathophysiological implications (II). Neurologia 29: 42-55 (2014).
148. McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 126: 479-497 (2013).
149. Rohn TT. The triggering receptor expressed on myeloid cells 2: "TREM-ming" the inflammatory component associated with Alzheimer’s disease. Oxid Med Cell Longev 2013: 860959 (2013).
150. Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, et al. Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization. Brain 136: 2677-2696 (2013).
151. Hailer NP, Grampp A, Nitsch R. Proliferation of microglia and astrocytes in the dentate gyrus following entorhinal cortex lesion: a quantitative bromodeoxyuridine-labelling study. Eur J Neurosci 11: 3359-3364 (1999).
152. Fiala JC. Mechanisms of amyloid plaque pathogenesis. Acta Neuropathol 114: 551-571 (2007).
153. Frackowiak J, Wisniewski HM, Wegiel J, Merz GS, Iqbal K, Wang KC. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol 84: 225-233 (1992).
154. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9: 1118-1127 (2010).
155. Toledano A, Alvarez MI, Toledano-Diaz A. Envejecimiento cerebral normal y patologico: continuum fisiopatologico o dualidad de procesos involutivos. An Real Acad Farm 80: 500-539 (2014).
156. Chiarini A, Dal Pra I, Menapace L, Pacchiana R, Whitfield JF, Armato U. Soluble amyloid beta-peptide and myelin basic protein strongly stimulate, alone and in synergism with combined proinflammatory cytokines, the expression of functional nitric oxide synthase-2 in normal adult human astrocytes. Int J Mol Med 16: 801-807 (2008).
157. Chiarini A, Gardenal E, Whitfield JF, Chakravarthy B, Armato U, Dal Pra I. Preventing the spread of Alzheimer’s disease neuropathology: a role for calcilytics? Curr Pharm Biotechnol 16: 696-706 (2015).
158. Chiarini A, Dal Pra I, Marconi M, Chakravarthy B, Whitfield JF, Armato U. Calcium-sensing receptor (CaSR) in human brain’s pathophysiology: roles in late-onset Alzheimer’s disease (LOAD). Curr Pharm Biotechnol 10: 317-326 (2009).
159. Venkat P, Chopp M, Chen J. Models and mechanisms of vascular dementia. Exp Neurol 15. pii: S0014-4886(15)00153-3 (2015).
160. Bhogal P, Mahoney C, Graeme-Baker S, Roy A, Shah S, Fraioli F, Cowley P, Jager HR. The common dementias: a pictorial review. Eur Radiol 23: 3405-3417 (2013).
161. Yamada M. Cerebral amyloid angiopathy: emerging concepts. J Stroke 17: 17-30 (2015).
162. Claassen JA. New cardiovascular targets to prevent late onset Alzheimer disease. Eur J Pharmacol 763(PtA): 131-4 (2015)
163. Toledano A, Alvarez MI, Lopez-Rodriguez AB, Toledano-Diaz A, Fernandez-Verdecia CI. Does Alzheimer’s disease exist in all primates? Alzheimer pathology in non-human primates and its pathophysiological implications (I). Neurologia 27: 354-369 (2012).
164. Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease. Alzheimers Dement pii: S1552-5260(14)02862-3 (2014)
165. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier, an overview: structure, regulation, and clinical implications. Neurobiol Dis 16: 1-13 (2004).
166. Jessen NA, Munk AS, Lundgaard I, Nedergaard M. The Glymphatic System: A Beginner’s Guide. Neurochem Res 40(12): 2583-2599 (2015).
167. Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, et al. Formation and maintenance of Alzheimer’s disease beta-amyloid plaques in the absence of microglia. Nat Neurosci 12: 1361-1363 (2009).
168. Dal Pra I, Chiarini A, Pacchiana R, Gardenal E, Chakravarthy B, Whitfield JF, Armato U. Calcium-sensing receptors of human astrocyte-neuron teams: amyloid-β-driven mediators and therapeutic targets of Alzheimer’s disease. Curr Neuropharmacol 12: 353-364 (2014).
169. Alberdi E, Wyssenbach A, Alberdi M, Sanchez-Gomez MV, Cavaliere F, Rodriguez JJ, Verkhratsky A, et al. Ca(2+) -dependent endoplasmic reticulum stress correlates with astrogliosis in oligomeric amyloid β-treated astrocytes and in a model of Alzheimer’s disease. Aging Cell 12: 292-302 (2013).
170. Dal Pra I, Whitfileld JF, Pacchiana R, Bonafini C, Talacchi A, Chakravarthy B, et al. The amyloid-β42 proxy, amyloid-β(25-35), induces normal human cerebral astrocytes to produce amyloid-β42. J Alzheimers Dis 24: 335-347 (2011).
171. Chiarini A, Whitfield J, Bonafini C, Chakravarthy B, Armato U, Dal Pra I. Amyloid-β(25-35), an amyloid-β(1-42) surrogate, and proinflammatory cytokines stimulate VEGF-A secretion by cultured, early passage, normoxic adult human cerebral astrocytes. J Alzheimers Dis 21: 915-926 (2010).